Investigational New Drugs

, 27:83 | Cite as

Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma

  • Thomas W. Flaig
  • Fernando J. Kim
  • Francisco G. La Rosa
  • Kathryn Breaker
  • Jonathan Schoen
  • Paul D. Russ


Pneumatosis Intestinal perforations Sunitinib treatment Renal cell carcinoma 


  1. 1.
    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124 DOI 10.1056/NEJMoa065044 PubMedCrossRefGoogle Scholar
  2. 2.
    Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860–1869 DOI 10.1245/s10434-006-9337-9 PubMedCrossRefGoogle Scholar
  3. 3.
    Sugrue M, Kozloff M, Hainsworth J et al (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24:3535Google Scholar
  4. 4.
    Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186 DOI 10.1200/JCO.2007.12.0782 PubMedCrossRefGoogle Scholar
  5. 5.
    Gray J, Murren J, Sharma A et al (2007) Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol 2:571–573 DOI 10.1097/JTO.0b013e31805fea51 PubMedCrossRefGoogle Scholar
  6. 6.
    Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35 DOI 10.1200/JCO.2005.02.2194 PubMedCrossRefGoogle Scholar
  7. 7.
    Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRefGoogle Scholar
  8. 8.
    Gore M, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:5010Google Scholar
  9. 9.
    Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342 DOI 10.1056/NEJMoa032691 PubMedCrossRefGoogle Scholar
  10. 10.
    Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019 DOI 10.1200/JCO.2007.14.9930 PubMedCrossRefGoogle Scholar
  11. 11.
    Garcia AA, Hirte H, Fleming F et al (2008) Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortium. J Clin Oncol 26:76–82 DOI 10.1200/JCO.2007.12.1939 PubMedCrossRefGoogle Scholar
  12. 12.
    Berger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 25:5165–5177 DOI 10.1200/JCO.2007.11.5345 CrossRefGoogle Scholar
  13. 13.
    Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676 DOI 10.1056/NEJMoa072113 PubMedCrossRefGoogle Scholar
  14. 14.
    Sandler A, Gray R, Perry MC (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542–2550 DOI 10.1056/NEJMoa061884 PubMedCrossRefGoogle Scholar
  15. 15.
    Heng Y, Schuffler MD, Haggitt RC et al (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747–1758PubMedGoogle Scholar
  16. 16.
    Asmis TR, Chung KY, Teitcher JB et al (2007) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95–96 DOI 10.1007/s10637-007-9094-z PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Thomas W. Flaig
    • 1
  • Fernando J. Kim
    • 2
  • Francisco G. La Rosa
    • 3
  • Kathryn Breaker
    • 4
  • Jonathan Schoen
    • 5
  • Paul D. Russ
    • 6
  1. 1.Department of Medicine, Division of Medical OncologyUniversity of Colorado Denver School of MedicineAuroraUSA
  2. 2.Department of Surgery, Division of UrologyUniversity of Colorado Denver School of MedicineAuroraUSA
  3. 3.Department of PathologyUniversity of Colorado Denver School of MedicineAuroraUSA
  4. 4.Clinical Investigations CoreUniversity of Colorado DenverAuroraUSA
  5. 5.Department of SurgeryUniversity of Colorado Denver School of MedicineAuroraUSA
  6. 6.Department of RadiologyUniversity of Colorado Denver School of MedicineAuroraUSA

Personalised recommendations